GentleGen high-throughput automated production line enables 24-hour unmanned production, fundamentally changing the traditional wet experiment situation of low throughput and insufficient standardization. Relying on the GentSynExp 3.0 fully automated platform, GentleGen has built a one-stop solution covering gene design, protein expression, and affinity characterization.

Sun Jian, founder and CEO of GentleGen, stated: "The collaboration with Wecomput is a key step in GentleGen deepening of its 'automation + intelligence' strategy. We will provide the most efficient verification foundation for AI design through a fully automated platform, combining predictive and delivery capabilities to truly shorten the R&D cycle. ”

Ge Hu, founder and CEO of Wecomput, stated: "GentleGen technological accumulation in end-to-end automated life science application scenarios is impressive. The collaboration between the two parties will truly bring AI design to 'implementation,' forming a data loop through rapid wet experiment verification, continuously optimizing models, and providing practical and user-friendly solutions for the industry. ”

This strategic partnership marks a shift from a breakthrough in AI-driven gene drug development to a systematic industry collaboration. GentleGen and Wecomput will join forces with an innovative model of "AI design + GentleGen validation" to inject new momentum into the global gene drug industry.

GentleGen was founded in 2022 and is headquartered in Suzhou. It is a national high-tech enterprise centered on "AI + Automation," dedicated to building a full-chain automated service platform covering gene design, synthesis, validation, and protein expression. The company has established a headquarters laboratory in Suzhou, a fully automated gene synthesis factory in Lianyungang, and satellite laboratories in Tianjin and Wuhan.

GentleGen has taken the lead in building a dry-wet closed-loop system covering three major areas: antibody drugs, oligonucleotide drugs, and synthetic biology: "AI design—automated synthesis—rapid validation—data return." Achieve 24-hour unmanned production, continuously accumulating high-quality wet experiment data through high-throughput automation capabilities.

To date, GentleGen has accumulated nearly a thousand clients and is driving the data flywheel forward with "AI + automation" as its engine, building the next-generation infrastructure for life sciences R&D.

Wecomput is committed to "computational technology-driven innovative drug R&D." Based on a deep understanding of the innovative drug R&D process, it integrates artificial intelligence, biophysics, and high-performance computing technologies to create a uniquely automated platform, intelligent and digital platform for drug molecule generation, design, and simulation. It is expected to revolutionize traditional drug discovery methods and drive the development of innovative drugs such as small molecules, proteins, antibodies, peptides, and nucleic acids. Core team members come from internationally renowned AI pharmaceutical companies, leading pharmaceutical companies, well-known internet companies, and 985 universities, possessing rich experience, deep understanding, and passionate passion in interdisciplinary fields such as pharmaceuticals, life sciences, artificial intelligence, and software development.

The parent company, Beijing Zhongda Weixin Technology Co., Ltd., was registered in 2015 and selected as a National High-Tech Enterprise. In 2021, it received equity investment from Sequoia Capital and was selected as a senior member of the NVIDIA Inception program. To date, Wecomput has served hundreds of clients both domestically and internationally, covering numerous biopharmaceutical companies, universities, hospitals, and research institutions, and has dedicated itself to building the independently developed molecular digital intelligent computing platform WeMol.